Losartan: Phase III discontinued

Researchers at the VA and colleagues said the double-blind, U.S. Phase III VA NEPHRON-D trial in 1,448 Type II diabetics with overt nephropathy was stopped

Read the full 250 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE